Filtered By:
Specialty: Drugs & Pharmacology
Infectious Disease: Hepatitis C
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chro...
Source: Frontiers in Pharmacology - May 11, 2021 Category: Drugs & Pharmacology Source Type: research

Interferon‐based therapy reduces risk of stroke in chronic hepatitis C patients: a population‐based cohort study in Taiwan
ConclusionsInterferon‐based therapy may reduce the long‐term risk of stroke in patients with chronic HCV infection.
Source: Alimentary Pharmacology and Therapeutics - June 29, 2013 Category: Drugs & Pharmacology Authors: C.‐S. Hsu, J.‐H. Kao, Y.‐C. Chao, H. H. Lin, Y.‐C. Fan, C.‐J. Huang, P.‐S. Tsai Tags: Original Article Source Type: research

Associations of chronic hepatitis C with metabolic and cardiac outcomes
ConclusionsChronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes and hypertension) and congestive heart failure.
Source: Alimentary Pharmacology and Therapeutics - February 5, 2013 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, E. Elsheikh Tags: Original Article Source Type: research